2022 Year in Review - Multiple Myeloma

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
2022 Year in Review - Multiple Myeloma | February 17, 2023
In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.
Read More
ALLO-715, an Allogeneic Anti-BCMA CAR T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: Results from UNIVERSAL
2022 Year in Review - Multiple Myeloma | February 17, 2023
Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.
Read More
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
2022 Year in Review - Multiple Myeloma | February 17, 2023
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.
Read More
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
2022 Year in Review - Multiple Myeloma | February 17, 2023
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.
Read More
Once-Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: The SKylaRk Trial
2022 Year in Review - Multiple Myeloma | February 17, 2023
A phase 2 study of isatuximab added to weekly carfilzomib, lenalidomide, and dexamethasone demonstrated promising efficacy and safety in transplant-eligible patients with newly diagnosed multiple myeloma.
Read More
Iberdomide, a Cereblon E3 Ligase Modulator, plus Dexamethasone Demonstrated Activity in Heavily Pretreated Patients with Multiple Myeloma
2022 Year in Review - Multiple Myeloma | February 17, 2023
Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial.
Read More
Evaluating Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
2022 Year in Review - Multiple Myeloma | February 17, 2023
Meta-analysis suggests that lenalidomide-carfilzomib may be the most effective maintenance treatment in patients with newly diagnosed multiple myeloma.
Read More
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
2022 Year in Review - Multiple Myeloma | February 17, 2023
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
Read More
GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma
2022 Year in Review - Multiple Myeloma | February 17, 2023
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
Read More
Subgroup Analysis of CANDOR-Evaluated Outcomes with Carfilzomib plus Dexamethasone and Daratumumab Based on Cytogenetic Risk
2022 Year in Review - Multiple Myeloma | February 17, 2023
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
Read More
Loading More Articles
Page 1 of 3
Results 1 - 10 of 25

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512